About 30 results found for searched term "CK2 inhibitor 2" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M30749 | UCK2 Inhibitor-2 | Dehydrogenase |
| UCK2 Inhibitor-2 is a non-competitive uridine-cytidine kinase 2 (UCK2) inhibitor with an IC50 value of 3.8 µM. UCK2 Inhibitor-2 can suppress uridine salvage in cells. | ||
| M45289 | CK2 inhibitor 2 | Casein Kinase |
| CK2 inhibitor 2 is a potent, selective and orally active CK2 inhibitor with an IC50 value of 0.66 nM.CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2 and possesses good anti-proliferative and anti-tumor activity. | ||
| M2523 | CK-636 | Actin-Related Protein |
| CK-0944636 | ||
| CK-636 is an Arp2/3 complex inhibitor with IC50 of 4 μM, 24 μM and 32 μM for inhibition of actin polymerization induced by human, fission yeast and bovine Arp2/3 complex, respectively. | ||
| M3354 | Carbamazepine | Sodium Channel |
| CBZ; NSC 169864 | ||
| Carbamazepine is a sodium channel inhibitor with an IC50 of 131 μM when treated with synaptosomes in rat brain. It can be used in trigeminal neuralgia research. Carbamazepine blocks voltage gated Na+, Ca2+, and K+ channels, and is also a HDAC inhibitor (IC50=2 μM). | ||
| M6102 | Pembrolizumab | PD-1/PD-L1 |
| Lambrolizumab; MK-3475 | ||
| Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). | ||
| M6420 | AIM-100 | Others |
| AIM100 | ||
| AIM-100 is a potent and selective Ack1 (TNK2) inhibitor (IC50 = 22 nM). | ||
| M8125 | Quinalizarin | Casein Kinase |
| Quinalizarin is a potent (IC50 = 110 nM), ATP-competitive, and highly selective (IC50 > 1 μM for CK1 and 72 other kinases) inhibitor of casein kinase II (CK2), with a Ki value of approximately 50 nM and an IC50 of 110 nM.Quinalizarin induces apoptosis in some cancer cells. Quinalizarin can induce apoptosis in some cancer cells.) | ||
| M10561 | IMP-1088 | DNA/RNA Synthesis |
| IMP1088 | ||
| IMP-1088 is a novel potent and selective blocker of N-myristoylation in cells. IMP-1088 is also a potent human N-myristoyltransferases NMT1 and NMT2 dual inhibitor with IC50s of <1 nM for HsNMT1 and HsNMT2. | ||
| M13593 | Silmitasertib sodium salt | Casein Kinase |
| CX-4945 sodium salt | ||
| Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'. | ||
| M13731 | ROCK inhibitor-2 | ROCK |
| ROCK inhibitor-2 is a selective dual ROCK1 and ROCK2 inhibitor with IC50s of 17 nM and 2 nM, respectively. | ||
| M14425 | LY2183240 | FAAH |
| LY2183240 is a highly potent blocker of anandamide uptake (IC50= 270 pM; Ki=540 nM). LY2183240 is a potent, covalent inhibitor of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) with an IC50 of 12.4 nM. | ||
| M28240 | AZD4320 | Bcl-2 |
| AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. | ||
| M28436 | Zidebactam | Antibiotic |
| WCK-5107 | ||
| Zidebactam (WCK-5107) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL. | ||
| M28823 | Zidebactam sodium salt | Antibiotic |
| WCK-5107 sodium salt | ||
| Zidebactam sodium salt (WCK-5107 sodium salt) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL. | ||
| M28890 | WCK-4234 | Antibiotic |
| WCK-4234 is a potent β-lactamase inhibitor. WCK-4234 inhibits class A, C, and D β-lactamases activity. WCK-4234 lacks direct antibacterial activity. WCK-4234 potentiates imipenem and meropenem against Enterobacteriaceae with OXA-48/OXA-181 or KPC enzymes, or with combinations of impermeability and AmpC or ESBL activity. WCK-4234 distinctively overcomes resistance mediated by OXA-type carbapenemases. | ||
| M29862 | KRAS inhibitor-9 | Ras |
| KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells. | ||
| M30022 | SRPIN803 | Casein Kinase |
| SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC50s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration. | ||
| M30518 | ARP-100 | MMP |
| ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1＇ pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM). | ||
| M30853 | TMCB | Casein Kinase |
| TMCB is a selective, ATP-competitive CK2 (casein kinase II) inhibitor with distinct Ki values of 83 nM and 21 nM for the two different catalytic CK2 subunits α and α', respectively. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M31200 | CK7 | CDK |
| CK-7 | ||
| CK7 is a Cdk2/9 inhibitor, which can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. | ||
| M41415 | CK1-IN-2 | Casein Kinase |
| CK1-IN-2 is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively. | ||
| M41417 | CK2-IN-7 | Casein Kinase |
| CK2-IN-7 is an inhibitor of casein kinase 2 (CK2). | ||
| M41592 | THK01 | ROCK |
| THK01 is a potent ROCK2 inhibitor with IC50 values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively. | ||
| M45287 | CK2/ERK8-IN-1 | Casein Kinase |
| CK2/ERK8-IN-1 is a dual inhibitor of casein kinase 2 (CK2) (Ki 0.25 µM) and ERK8 (MAPK15, ERK7), both with IC50s of 0.50 µM. In addition, CK2/ERK8-IN-1 binds to PIM1, HIPK2, and DYRK1A with Ki values of 8.65 µM, 15.25 µM, and 11.9 µM, respectively. 15.25 µM and 11.9 µM, respectively, and also has pro-apoptotic activity. | ||
| M45293 | BRD4/CK2-IN-1 | Casein Kinase |
| BRD4/CK2-IN-1 is a potent, orally active dual-targeted inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2) with IC50 values of 180 nM and 230 nM, respectively.BRD4/CK2-IN-1 exhibits potent anticancer activity without significant toxicity and induces apoptosis and autophagy-related cell death in triple-negative breast cancer (TNBC). autophagy-related cell death in triple negative breast cancer (TNBC). | ||
| M45297 | CK2-IN-3 | Casein Kinase |
| CK2-IN-3 is a selective and potent CK2 inhibitor (Kd: 12 nM) with IC50 values of 1.51 μM (CK2α), 7.64 μM (CK2α') and can be used in cancer-related studies. | ||
| M45300 | CK2/PIM1-IN-1 | Casein Kinase |
| CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1 with IC50 values of 3.787 μM and 4.327 μM for the effects of CK2 and PIM1, respectively.CAS 번호410483-84-5 | ||
| M45303 | CK2 inhibitor 3 | Casein Kinase |
| CK2 inhibitor 3 is a potent CK2 inhibitor with an IC50 of 280 nM that significantly affects tumor cell viability and exhibits significant selectivity for a panel of 320 kinases. | ||
| M45305 | CK2-IN-9 | Casein Kinase |
| CK2-IN-9 is a potent selective inhibitor of CK2 kinase with an IC50 of 3 nM, and also reduces the reporter activity of Wnt with an IC50 of 75 nM. In addition, CK2-IN-9 is characterized by low exposure (AUC=0.36 μM/h) and high clearance (CL=65 mL/min/kg) in rats. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
